Navigation Links
d'Oliveira & Associates Releases New Byetta Infographic on Potential Kidney and Pancreas Health Risks Associated with the Drug
Date:3/24/2013

(PRWEB) March 24, 2013

Approved by the FDA in April 2005, Byetta is a type-2 diabetes drug used to control glucose levels. Adverse Events, an organization that standardizes FDA adverse event reports, has processed 38,730 adverse events concerning Byetta and 1,733 of these reports allege a link between the drug and cases of pancreatitis (i). According to the USA Today article, “Popular diabetes drugs may raise pancreatic cancer risk, study suggests,” pancreatitis and cancer were two of the health concerns raised by a recent medical study (ii). The article goes on to report a study completed by the Research Center at the University of California, Los Angeles that found a six-fold increase of pancreatitis in patients taking Byetta or Januvia and it also increased the risk of pancreatic cancer by 2.9 times and thyroid cancer in patients taking the drug (ii).

Bloomberg reported the results of a Byetta medical study published in the Journal of the American Medical Association for Internal Medicine; the study followed 1,269 patients with type-2 diabetes who filled at least one prescription for a diabetes drug in a three-year period (iii). Out of the 145 patients who developed pancreatitis, 87 of them were taking Byetta or Januvia, the study suggested that Byetta and Januvia doubled the risk of pancreatitis compared to other diabetes drugs (iii). The study’s author, Dr. Sonal Singh, told Bloomberg that, “we really need to know more about these drugs as pancreatitis is on the pathway to pancreatic cancer (iii).”

The Byetta infographic provides a timeline detailing major events in the development of the drug. For example, from April 2005 until October 2008, the FDA received 78 complaints of kidney damage in patients using Byetta, 62 of these complaints reported kidney failure (iv). Visit the Byetta section of d’Oliveira & Associates or view the infographic HERE.

If you or a loved one has suffered pancreatic, liver, or thyroid cancer, after taking Byetta, you may want to speak with a personal injury lawyer. A dangerous drug lawyer familiar with the diabetes injection can investigate a legal claim. d’Oliveira & Associates is working with some of the most experienced Byetta lawyers in the country, who are handling these cases. And, there is no fee until you receive a Byetta settlement or award.

Please contact the law offices of d'Oliveira & Associates at 1-800-992-6878 or fill out a contact form for a free legal consultation.

(i) http://www.adverseevents.com/drugdetail.php?AEDrugID=1260&BrandName=BYETTA
(ii) http://usatoday30.usatoday.com/news/health/medical/health/medical/story/2011-09-23/Popular-diabetes-drugs-may-raise-pancreatic-cancer-risk-study-suggests/50531776/1
(iii) http://www.bloomberg.com/news/2013-02-25/merck-bristol-diabetes-drugs-linked-to-pancreatitis-risk.html
(iv) http://www.fda.gov/safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm188703.htm

Read the full story at http://www.prweb.com/releases/2013/3/prweb10548949.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. d'Oliveira & Associates Offers “No Win - No Fee Promise” on Topamax Cases
2. d'Oliveira & Associates Releases Zimmer Knee Infographic Providing Important Safety Information on High-Flex Knees
3. d'Oliveira & Associates Helps Massachusetts Man Receive $100,000 in Auto Accident Settlement
4. The Law Firm of d'Oliveira & Associates Now Offers a No Win - No Fee Promise in Mirena IUD Cases
5. d'Oliveira & Associates Releases Fresenius Infographic about the FDA Recall of NaturaLyte and GranuFlo
6. D'Oliveira & Associates Now Offers a No Win No Fee Promise in Zithromax Cases
7. d'Oliveira & Associates Helps Fall River, MA Teenager Receive $38,500 in Auto Accident Settlement
8. d'Oliveira & Associates Notes the Announcement of Zoloft Birth Defects Multidistrict Litigation (MDL) Set to Start in Mid-September 2014
9. The Law Firm of d'Oliveira and Associates Now Offers a No Win - No Free Promise in Nexium Cases
10. The Law Firm of d'Oliveira & Associates Now Offers a No Win - No Fee Promise in Fosamax Cases
11. d'Oliveira & Associates Helps Newport Woman Receive $150,000 Settlement for Auto Accident; Case: MI-11889
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... CA (PRWEB) , ... February 11, 2016 , ... ... was held in San Diego, CA, on February 6th & 7th, 2016 according to ... for those who were not invited to the NFL’s combine in Indianapolis,” says Husted. ...
(Date:2/11/2016)... Ore. (PRWEB) , ... February 11, 2016 , ... ... Medicaid coverage results in significantly higher rates of several common cancer screenings, especially ... resulting in better outcomes and survival rates. , The study,“What Does Medicaid ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... (WMIS), known as the World Molecular Imaging Congress (WMIC), will be held in ... the 2016 meeting is “Imaging Biology…Improving Therapy.” The congress will highlight and emphasize ...
(Date:2/10/2016)... ... 10, 2016 , ... LaserShip, a regional parcel carrier that services the eastern ... Michigan last Friday in order to aid in the Flint water crisis. In 2014, ... facility located in Clio, only 15 miles away from Flint. , “We have deep ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... its revolutionary new 2.0 version at the International Roofing Expo in Orlando, Florida ... of the world's most advanced weather technology in the hands of consumers, roofing ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... OR AKIVA, Israel , February 10, ... Ltd., a leader in the field of cartilage repair, ... on February 5, 2016. The $15 million investment was ... leading Chinese pharmaceutical manufacturer, and was joined by existing ... Financial Holdings and both the Technion Research & Development ...
(Date:2/10/2016)... New York , February 10, 2016 ... Growth, Trends and Forecast 2015 - 2023 ", reveals that ... rather slow growth from 2015 to 2023 owing to patent ... a meager CAGR of 1.30% during the forecast period, the ... to US$38.9 bn in 2023. --> Antibacterial Drugs ...
(Date:2/10/2016)... 2016  Silicon Biosystems Menarini Inc., a developer ... uncover the biological complexities of disease at the ... of innovative technologies for genomics research, today announced ... enabling translational researchers to obtain high-quality sequencing results ... and normal cells in an optimized and seamless ...
Breaking Medicine Technology: